Antagonistic DR3 ligands

摘要

The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.

主权项

1. An isolated monovalent antagonistic anti-DR3 antibody, the antibody comprising a heavy chain variable region comprising a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 and a light chain variable region comprising a light chain CDR1, a light chain CDR2, and a light chain CDR3, the heavy chain CDR1 comprising an amino acid sequence corresponding to Kabat residues 31-35 of SEQ ID NO:10; the heavy chain CDR2 comprising an amino acid sequence corresponding to Kabat residues 50-58 of SEQ ID NO:10; the heavy chain CDR3 comprising an amino acid sequence corresponding to Kabat residues 95-102 of SEQ ID NO:10; the light chain CDR1 comprising an amino acid sequence corresponding to Kabat residues 24-34 of SEQ ID NO:11; the light chain CDR2 comprising an amino acid sequence corresponding to Kabat residues 50-56 of SEQ ID NO:11; and the light chain CDR3 comprising an amino acid sequence corresponding to Kabat residues 89-97 of SEQ ID NO:11.